BG66113B1 - Комбиниран химиотерапевтичен състав - Google Patents

Комбиниран химиотерапевтичен състав

Info

Publication number
BG66113B1
BG66113B1 BG107281A BG10728102A BG66113B1 BG 66113 B1 BG66113 B1 BG 66113B1 BG 107281 A BG107281 A BG 107281A BG 10728102 A BG10728102 A BG 10728102A BG 66113 B1 BG66113 B1 BG 66113B1
Authority
BG
Bulgaria
Prior art keywords
platinum
antitumor agent
methylpyridine
agent
pharmaceutical composition
Prior art date
Application number
BG107281A
Other languages
English (en)
Other versions
BG107281A (bg
Inventor
Mark Smith
Trevor Stephens
Original Assignee
Anormed Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc. filed Critical Anormed Inc.
Publication of BG107281A publication Critical patent/BG107281A/bg
Publication of BG66113B1 publication Critical patent/BG66113B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретението се отнася до фармацевтичен състав, терапевтичен продукт и кит, включващи пространствено запречено платинено координационно съединение и неплатинен антитуморен агент, и фармацевтично приемлив носител или разтворител, до използването им за производство на медикамент за инхибиране растежа на туморните клетки при човек със съответното заболяване. Използва се ефективно количество терапевтичен продукт или фармацевтичен състав съгласно изобретението, което инхибира растежа на туморните клетки, по-специално, когато пространствено запреченото платинено координационно съединение е (SР-4-3) - (сis-аминодихлоро - [2-метилпиридин] платина(II) (ZD0473) или негов лекарствен предшественик и неплатиненият антитуморен агент е избран от групата Таксол, Гемцитабин, Навелбин, Доксил, 5-FU и Таксотер. Съгласно изобретението се използва ефективно количество (SP-4-3)-(cis-амин-дихлоро - [2-метилпиридин] платина (II) (ZD0473) в комбинация с антитуморно ефективно количество неплатинен антитуморен агент при едновременно и/или последователно или поотделно прилагане на определените количества, като неплатиненият агент е паклитаксел или доцетаксел, прилаган отделно от и преди ZD0473.
BG107281A 2000-05-18 2002-11-15 Комбиниран химиотерапевтичен състав BG66113B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0011903.2A GB0011903D0 (en) 2000-05-18 2000-05-18 Combination chemotherapy
PCT/GB2001/002060 WO2001087313A1 (en) 2000-05-18 2001-05-10 Combination chemotherapy

Publications (2)

Publication Number Publication Date
BG107281A BG107281A (bg) 2003-09-30
BG66113B1 true BG66113B1 (bg) 2011-05-31

Family

ID=9891766

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107281A BG66113B1 (bg) 2000-05-18 2002-11-15 Комбиниран химиотерапевтичен състав

Country Status (28)

Country Link
US (1) US20040053882A1 (bg)
EP (2) EP1530969A1 (bg)
JP (2) JP2003533485A (bg)
KR (2) KR20030014228A (bg)
CN (3) CN100411628C (bg)
AR (1) AR030281A1 (bg)
AU (3) AU2001252442B8 (bg)
BG (1) BG66113B1 (bg)
BR (1) BR0110837A (bg)
CA (1) CA2410067A1 (bg)
CZ (1) CZ20023766A3 (bg)
EE (1) EE05261B1 (bg)
GB (1) GB0011903D0 (bg)
HK (1) HK1049446A1 (bg)
HU (1) HUP0302130A3 (bg)
IL (1) IL151959A0 (bg)
IS (1) IS6571A (bg)
MX (1) MXPA02011247A (bg)
MY (1) MY138923A (bg)
NO (1) NO332079B1 (bg)
NZ (1) NZ521632A (bg)
PL (1) PL357721A1 (bg)
RU (2) RU2429838C2 (bg)
SK (1) SK16392002A3 (bg)
TW (1) TW200637565A (bg)
UA (1) UA81098C2 (bg)
WO (1) WO2001087313A1 (bg)
ZA (1) ZA200209279B (bg)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US8791081B2 (en) * 1999-08-13 2014-07-29 Case Western Reserve University MGMT inhibitor combination for the treatment of neoplastic disorders
ES2275931T5 (es) * 2001-12-03 2018-10-23 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
BRPI0613796A2 (pt) * 2005-06-07 2011-02-15 Univ Yale composicões farmacêuticas e seus usos, e métodos de tratamento de cáncer e outras condições ou estados patológicos, por meio do uso de clevudina (lfmau) e telbivudina (ldt)
US7616481B2 (en) * 2005-12-28 2009-11-10 Sandisk Corporation Memories with alternate sensing techniques
MX2008014953A (es) * 2006-05-26 2009-03-05 Bayer Healthcare Llc Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer.
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
WO2009011861A1 (en) * 2007-07-16 2009-01-22 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
WO2009099634A2 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Picoplatin and amrubicin to treat lung cancer
CN101302235B (zh) * 2008-06-30 2011-06-01 昆明贵研药业有限公司 甲啶铂的提纯
US20130211384A1 (en) * 2010-07-28 2013-08-15 Fondazione Irccs Istituto Nazionale Dei Tumori Therapeutic agent, composition including said agent, implantable device and process for the treatment of cervical cancer and/or for the prevention of the formation of neoplasms in correspondence of the cervix in a human female genital system
KR101389072B1 (ko) * 2011-05-25 2014-04-23 가톨릭대학교 산학협력단 ＢＨＲＦ１ 발현 억제를 위한 ｓｉＲＮＡ 및 이를 포함하는 조성물
WO2017060661A1 (en) * 2015-10-05 2017-04-13 Nucana Biomed Limited Combination therapy
ES2955524T3 (es) 2017-05-16 2023-12-04 Ability Pharmaceuticals S A Una combinación farmacéutica para el tratamiento de un cáncer
CN113694205B (zh) * 2021-09-23 2023-05-16 山东第一医科大学(山东省医学科学院) 5-ht受体抑制剂和顺铂在制备治疗肝癌的药物中的应用

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1432562A (en) * 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum co-ordination compounds
US4329299A (en) * 1979-08-23 1982-05-11 Johnson, Matthey & Co., Limited Composition of matter containing platinum
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
IL63658A0 (en) * 1980-09-03 1981-11-30 Johnson Matthey Plc Co-ordination compound of platinum and its preparation
US4533502A (en) * 1983-02-22 1985-08-06 Rochon Fernande D Platinum (II) compounds and their preparation
EP0167310B1 (en) * 1984-06-27 1991-05-29 Johnson Matthey Public Limited Company Platinum co-ordination compounds
US5082655A (en) * 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
FR2586428B1 (fr) * 1985-08-26 1988-11-25 Pasteur Institut Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
CA1327039C (en) * 1986-12-18 1994-02-15 Tetsushi Totani Ammine-alicyclic amine-platinum complexes and antitumor agents
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
CN1016693B (zh) * 1987-06-05 1992-05-20 北京工业大学 新顺铂铬合物的制备方法
GB9105037D0 (en) * 1991-03-09 1991-04-24 Johnson Matthey Plc Improvements in chemical compounds
US5244991A (en) * 1991-10-15 1993-09-14 Phillips Petroleum Company Olefin polymerization process
AU671605B2 (en) * 1991-11-15 1996-09-05 Smithkline Beecham Corporation Combination chemotherapy
ES2210239T3 (es) * 1992-04-01 2004-07-01 The Johns Hopkins University School Of Medicine Metodo para detectar acidos nucleicos de mamiferos aislados en heces y reactivos para el mismo.
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
US5624919A (en) * 1993-09-14 1997-04-29 The University Of Vermont And State Agricultural College Trans platinum (IV) complexes
GB9408218D0 (en) * 1994-04-26 1994-06-15 Johnson Matthey Plc Improvements in platinum complexes
WO1996001638A1 (en) * 1994-07-11 1996-01-25 Hoechst Marion Roussel, Inc. Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
CN1039813C (zh) * 1994-10-31 1998-09-16 西安五环(集团)股份有限公司 具抗癌效应的顺式-二氨-1,1-环戊二羧酸根合铂(ⅱ)的化合物及其合成方法
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9502799D0 (en) * 1995-02-14 1995-04-05 Johnson Matthey Plc Improvements in platinum complexes
CN1039588C (zh) * 1995-03-29 1998-08-26 邹娟 新的抗肿瘤铂络合物
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
NZ333099A (en) * 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
WO1999056742A1 (en) * 1998-05-04 1999-11-11 Auckland Uniservices Limited Chemotherapeutic treatment
DE19847618A1 (de) * 1998-10-15 2000-04-20 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6235782B1 (en) * 1998-11-12 2001-05-22 Rifat Pamukcu Method for treating a patient with neoplasia by treatment with a platinum coordination complex
IL145671A0 (en) * 1999-04-13 2002-06-30 Anormed Inc Process for preparing amine platinum complexes
US6413953B1 (en) * 1999-04-13 2002-07-02 Anormed Inc. Pt(IV) antitumor agent
EP1224303A2 (en) * 1999-10-18 2002-07-24 Emory University Tms1 compositions and methods of use
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20020102301A1 (en) * 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
KR20020075797A (ko) * 2000-02-16 2002-10-05 야마노우치세이야쿠 가부시키가이샤 엔도텔린 유발성 질환 치료제
AU2001246477A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
US6545010B2 (en) * 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
US20020110601A1 (en) * 2000-03-31 2002-08-15 Roman Perez-Soler Antineoplastic platinum therapeutic method and composition
AU2001277711A1 (en) * 2000-08-11 2002-02-25 Sumitomo Pharmaceuticals Co. Ltd. Remedies for cisplatin-tolerant cancer
US6894049B1 (en) * 2000-10-04 2005-05-17 Anormed, Inc. Platinum complexes as antitumor agents
US6544962B1 (en) * 2000-11-02 2003-04-08 Matrix Pharmaceutical, Inc. Methods for treating cellular proliferative disorders
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
US6673370B2 (en) * 2001-05-15 2004-01-06 Biomedicines, Inc. Oxidized collagen formulations for use with non-compatible pharmaceutical agents
MXPA04001071A (es) * 2001-08-06 2004-05-20 Astrazeneca Ab Dispersion acuosa que comprende nanoparticulas estables de un activo insoluble en agua y un excipiente como trigliceridos de cadena media (mct).
EP1424889A4 (en) * 2001-08-20 2008-04-02 Transave Inc PROCESS FOR TREATING LUNG CANCERS
DE10141528B4 (de) * 2001-08-24 2006-08-10 Faustus Forschungs Cie. Translational Cancer Research Gmbh Platin(II)- und Platin(IV)-Komplexe und ihre Verwendung
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
WO2003057128A2 (en) * 2001-12-11 2003-07-17 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
US7691833B2 (en) * 2002-03-01 2010-04-06 Trustees Of Dartmouth College Compositions and methods for preventing sporadic neoplasia in colon
US20040010553A1 (en) * 2002-07-15 2004-01-15 International Business Machines Corporation Peer to peer location based services
WO2004006859A2 (en) * 2002-07-16 2004-01-22 Sonus Pharmaceuticals, Inc. Platinum compound
CN1681478A (zh) * 2002-08-02 2005-10-12 川塞夫有限公司 铂聚集体及其制备方法
US20040156816A1 (en) * 2002-08-06 2004-08-12 David Anderson Lipid-drug complexes in reversed liquid and liquid crystalline phases
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
DE10256182A1 (de) * 2002-12-02 2004-06-24 Merck Patent Gmbh 2-Oxadiazolchromonderivate
DE502004006542D1 (de) * 2003-04-30 2008-04-30 Merck Patent Gmbh Chromenonderivate
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
BRPI0510963A (pt) * 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
MXPA06011658A (es) * 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
TW200600091A (en) * 2004-05-21 2006-01-01 Telik Inc Sulfonylethyl phosphorodiamidates
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
WO2006002119A2 (en) * 2004-06-18 2006-01-05 Gpc Biotech, Inc. Kinase inhibitors for treating cancers
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
BRPI0515567A (pt) * 2004-09-22 2008-07-29 Pfizer combinações terapêuticas compreendendo inibidor de poli (adp-ribose) polimerase
US20090065522A1 (en) * 2004-10-13 2009-03-12 Nadir Benouali Unit dose compliance monitoring and reporting device and system
WO2006071812A2 (en) * 2004-12-23 2006-07-06 H. Lee Moffitt Cancer Center And Research Institute Platinum iv complex inhibitor
WO2006090931A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の抗癌剤との新規併用
WO2006104668A2 (en) * 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
PT1888550E (pt) * 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Promotores de apoptose
NZ592132A (en) * 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190181A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
US20070190180A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007064658A2 (en) * 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
US8143236B2 (en) * 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
EP3231442B1 (en) * 2006-06-23 2019-12-25 ADC Therapeutics SA Polynucleotides and polypeptide sequences involved in cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
KR20090109130A (ko) * 2007-02-09 2009-10-19 포니아드 파마슈티칼즈, 인크. 캡슐화된 피코플라틴
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
AU2008260510A1 (en) * 2007-05-31 2008-12-11 Ascenta Therapeutics, Inc. Pulsatile dosing of gossypol for treatment of disease
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
EP2644192B1 (en) * 2007-09-28 2017-05-10 Pfizer Inc Cancer Cell Targeting Using Nanoparticles
WO2009099634A2 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Picoplatin and amrubicin to treat lung cancer

Also Published As

Publication number Publication date
CN101310719A (zh) 2008-11-26
JP2012062329A (ja) 2012-03-29
EP1283712A1 (en) 2003-02-19
EE05261B1 (et) 2010-02-15
HUP0302130A3 (en) 2005-06-28
RU2587013C2 (ru) 2016-06-10
EP1530969A1 (en) 2005-05-18
JP2003533485A (ja) 2003-11-11
UA81098C2 (uk) 2007-12-10
NO20025502L (no) 2002-11-15
MXPA02011247A (es) 2004-08-19
NO20025502D0 (no) 2002-11-15
MY138923A (en) 2009-08-28
RU2006122350A (ru) 2008-01-10
CA2410067A1 (en) 2001-11-22
BG107281A (bg) 2003-09-30
CN100411628C (zh) 2008-08-20
NO332079B1 (no) 2012-06-18
CZ20023766A3 (cs) 2003-03-12
AU2006201008A1 (en) 2006-04-06
IL151959A0 (en) 2003-04-10
TW200637565A (en) 2006-11-01
SK16392002A3 (sk) 2003-04-01
HUP0302130A2 (hu) 2003-11-28
AU2006201008C1 (en) 2009-08-13
RU2010117635A (ru) 2011-11-10
KR20030014228A (ko) 2003-02-15
IS6571A (is) 2002-09-27
US20040053882A1 (en) 2004-03-18
EE200200648A (et) 2004-06-15
AU2006201008B2 (en) 2009-01-08
AU2001252442B8 (en) 2006-05-04
PL357721A1 (en) 2004-07-26
BR0110837A (pt) 2003-03-11
NZ521632A (en) 2004-08-27
AR030281A1 (es) 2003-08-20
AU5244201A (en) 2001-11-26
HK1049446A1 (zh) 2003-05-16
GB0011903D0 (en) 2000-07-05
KR20090040926A (ko) 2009-04-27
AU2001252442B2 (en) 2006-03-23
CN1429114A (zh) 2003-07-09
WO2001087313A1 (en) 2001-11-22
RU2429838C2 (ru) 2011-09-27
CN101084886A (zh) 2007-12-12
ZA200209279B (en) 2004-02-16

Similar Documents

Publication Publication Date Title
BG66113B1 (bg) Комбиниран химиотерапевтичен състав
Fennelly et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
RU2767664C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
JP3361102B2 (ja) 医薬の経口生体利用率を増加させるための方法、組成物およびキット
ES2964764T3 (es) Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino
RU2003121768A (ru) Способ, лекарственная форма и наборы для повышения пероральной биологической доступности фармацевтических агентов
ATE514424T1 (de) Pharmazeutische zubereitungen von taxanen
JP2003533485A5 (bg)
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
CZ301482B6 (cs) Prostredky a použití ET743 k lécbe rakoviny
JP2009536956A (ja) 抗癌治療法
Dean-Colomb et al. Emerging agents in the treatment of anthracycline-and taxane-refractory metastatic breast cancer
Punt New drugs in the treatment of colorectal carcinoma
WO2006045541A1 (en) Treatment and prevention of multi-drug resistance
KR20030019296A (ko) 인체 환자에게 탁산을 경구 투여하는 방법 및 조성물
Mayerhofer et al. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy
KR20070089158A (ko) 암의 치료를 위한ｎ-(3-메톡시-5-메틸피라진-2-일)-2-(4-[1,3,4-옥사디아졸-2-일]페닐)피리딘-3-설폰아미드 및 항-유사분열제의 조합물
HU229258B1 (en) Combination of a taxane and a cyclin-dependent kinase inhibitor
KR20140022856A (ko) 치료적 요법
Crinò et al. Gemzar platinum combinations: phase III trials in non-small cell lung cancer
ZA200508696B (en) Use of irinotecan for treatment of resistant breast cancer
HUP0302599A2 (hu) Eljárás összetett kemoterápiás készítmények toxicitásának csökkentésére
RU2002133963A (ru) Комбинированная химиотерапия
JP2003535874A (ja) 置換アクリロイルジスタマイシン誘導体、タキサン類及び／又は代謝拮抗剤を含む腫瘍に対する併用療法
Saraiya et al. Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors